FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953591603> ?p ?o ?g. }

• W2953591603 endingPage "29" @default.
• W2953591603 startingPage "12" @default.
• W2953591603 abstract "Background: ART has brought significant change in morbidity and mortality among children on HAART. However, antiretroviral related adverse drug reactions are one of the leading causes of drug changes, poor adherence and treatment failure.Objective: To determine the prevalence, severity and time of occurrence of antiretroviral adverse drug reactions among HIV-1 infected children taking HAART at Tikur Anbesa Specialized Hospital.Methodology: This is a retrospective analytic cohort study conducted in the department of pediatrics and child health. A special questionnaire was designed to collect parameters from follow up charts of patients on HAART.Results: A total of 1000 children were enrolled and 600 were eligible and started HAART between Jan 2005-Jan 2010. Out of 600 on ART, 25 (4.2%) died, 75 (12.5%) lost, 50 (8.33%) transferred out and 450 (75%) continued ART until the time of data collection. Fifty patients on HAART were having incompletely filled charts and excluded from the study. Total eligible group for the study were 400 children on HAART of which 212(53%) were males and 188(47%) were females. Majority (83%) had started ART with immune category III and most of them were WHO grade III (50%) and IV (32%). The age at the beginning of ART ranges from 8-180 months and 50% of them were in the range of 60-120 months. There was a total of 12% (48/400) of drug changes due to various reasons. ARV related adverse drug reactions were the leading cause of drug change constituting 41.7% (20/48) of total drug changes. Treatment failure 31.25% (15/48), shifting regimen to FDC 16.7% (8/48) and TB treatment 10.4% (5/48) were other common reasons of drug changes. The prevalence of severe anemia (HCT<21%) was 3.13% (10/320) which occurred exclusively among children taking AZT containing regimen. The prevalence of NVP induced skin rash and hepatitis was 3.34% (6/177) and 1.7% (3/177) respectively. Three cases of neuropathy 3.8% (3/79) and two cases of lipo-dystrophy 2.5% (2/79) were recorded in d4T containing regimen. Chronic illness with concomitant non-ARV drug use had strong association with the development of anemia and hepatitis (P-value <0.005). No other predictive factor was found to have statistically significant association with commonly encountered adverse drug reactions.Conclusion: ARV related adverse drug reactions are the leading causes of drug changes among children on HAART at Tikur Anbesa Specialized Hospital. Skin rash, anemia, hepatitis, neuropathy and dystrophy are the major adverse drug reactions which required drug changes. Severe skin rash ascribed to nevirapine use appeared early in the course of antiretroviral therapy while neuropathy and lipo-dystrophy due to stavudine administration developed late in the course of treatment. In addition, moderate to severe anemia and hepatitis occurred in patients with chronic illness and concomitant non-ARV medications.Recommendation: Patient counseling regarding signs and symptoms of ARV related adverse drug reaction and time of occurrence is paramount. Early recognition of side effects and timely intervention could lead to reduction of morbidity and poor adherence. Due attention should be paid for children who have chronic illness and concomitant non-ARV medications. Finally, I recommend prospective trial to demonstrate all types of ARV related adverse drug reactions, grade severity, determine time of occurrence and identify risk factors." @default.
• W2953591603 created "2019-07-12" @default.
• W2953591603 creator A5018819392 @default.
• W2953591603 creator A5023365389 @default.
• W2953591603 creator A5026020619 @default.
• W2953591603 creator A5045611249 @default.
• W2953591603 date "2011-01-25" @default.
• W2953591603 modified "2023-10-06" @default.
• W2953591603 title "ANTIRETROVIRAL RELATED ADVERSE DRUG REACTIONS AMONG HIV-1 INFECTED CHILDREN ON FIRST LINE REGIMEN AT TIKUR ANBESA SPECIALIZED HOSPITAL, ADDIS ABABA-ETHIOPIA" @default.
• W2953591603 hasPublicationYear "2011" @default.
• W2953591603 type Work @default.
• W2953591603 sameAs 2953591603 @default.
• W2953591603 citedByCount "0" @default.
• W2953591603 crossrefType "journal-article" @default.
• W2953591603 hasAuthorship W2953591603A5018819392 @default.
• W2953591603 hasAuthorship W2953591603A5023365389 @default.
• W2953591603 hasAuthorship W2953591603A5026020619 @default.
• W2953591603 hasAuthorship W2953591603A5045611249 @default.
• W2953591603 hasConcept C126322002 @default.
• W2953591603 hasConcept C142462285 @default.
• W2953591603 hasConcept C167135981 @default.
• W2953591603 hasConcept C187212893 @default.
• W2953591603 hasConcept C197934379 @default.
• W2953591603 hasConcept C203014093 @default.
• W2953591603 hasConcept C2780035454 @default.
• W2953591603 hasConcept C2780542314 @default.
• W2953591603 hasConcept C2781413609 @default.
• W2953591603 hasConcept C2993143319 @default.
• W2953591603 hasConcept C2993432071 @default.
• W2953591603 hasConcept C3013748606 @default.
• W2953591603 hasConcept C3018457394 @default.
• W2953591603 hasConcept C3019165603 @default.
• W2953591603 hasConcept C71924100 @default.
• W2953591603 hasConcept C72563966 @default.
• W2953591603 hasConcept C98274493 @default.
• W2953591603 hasConceptScore W2953591603C126322002 @default.
• W2953591603 hasConceptScore W2953591603C142462285 @default.
• W2953591603 hasConceptScore W2953591603C167135981 @default.
• W2953591603 hasConceptScore W2953591603C187212893 @default.
• W2953591603 hasConceptScore W2953591603C197934379 @default.
• W2953591603 hasConceptScore W2953591603C203014093 @default.
• W2953591603 hasConceptScore W2953591603C2780035454 @default.
• W2953591603 hasConceptScore W2953591603C2780542314 @default.
• W2953591603 hasConceptScore W2953591603C2781413609 @default.
• W2953591603 hasConceptScore W2953591603C2993143319 @default.
• W2953591603 hasConceptScore W2953591603C2993432071 @default.
• W2953591603 hasConceptScore W2953591603C3013748606 @default.
• W2953591603 hasConceptScore W2953591603C3018457394 @default.
• W2953591603 hasConceptScore W2953591603C3019165603 @default.
• W2953591603 hasConceptScore W2953591603C71924100 @default.
• W2953591603 hasConceptScore W2953591603C72563966 @default.
• W2953591603 hasConceptScore W2953591603C98274493 @default.
• W2953591603 hasIssue "7" @default.
• W2953591603 hasLocation W29535916031 @default.
• W2953591603 hasOpenAccess W2953591603 @default.
• W2953591603 hasPrimaryLocation W29535916031 @default.
• W2953591603 hasRelatedWork W1533681707 @default.
• W2953591603 hasRelatedWork W2041270150 @default.
• W2953591603 hasRelatedWork W2041657458 @default.
• W2953591603 hasRelatedWork W2101996867 @default.
• W2953591603 hasRelatedWork W2110948862 @default.
• W2953591603 hasRelatedWork W2139329570 @default.
• W2953591603 hasRelatedWork W2140549488 @default.
• W2953591603 hasRelatedWork W2143443483 @default.
• W2953591603 hasRelatedWork W2144534753 @default.
• W2953591603 hasRelatedWork W2150924653 @default.
• W2953591603 hasRelatedWork W2167617127 @default.
• W2953591603 hasRelatedWork W2294082476 @default.
• W2953591603 hasRelatedWork W2416484022 @default.
• W2953591603 hasRelatedWork W2574356334 @default.
• W2953591603 hasRelatedWork W2587993242 @default.
• W2953591603 hasRelatedWork W2919583544 @default.
• W2953591603 hasRelatedWork W3168163513 @default.
• W2953591603 hasRelatedWork W3174315714 @default.
• W2953591603 hasRelatedWork W3191672137 @default.
• W2953591603 hasRelatedWork W2610931659 @default.
• W2953591603 hasVolume "7" @default.
• W2953591603 isParatext "false" @default.
• W2953591603 isRetracted "false" @default.
• W2953591603 magId "2953591603" @default.
• W2953591603 workType "article" @default.